Phase 1/2 Trial Combines GI-102 With Pasritamig to Strengthen T-Cell Immunotherapy in Advanced Prostate Cancer
A newly registered phase 1/2 clinical trial will investigate whether combining two immunotherapies with complementary mechanisms can improve treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). The study, known as JET-201, plans to enrol 107 patients in the United States and South Korea. The combination brings together pasritamig (JNJ-78278343), a bispecific antibody designed […]
